Get started
Author

Frances Hamkins-Indik

Observed names: F. Hamkins-Indik, F. Hamkins-indik
OpenAlex ID: A5043288388
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
2025 · Shilpa Singh, Catherine E. Gleason, et al. · Nature · 21
The potential of achiral sponge-derived and synthetic bromoindoles as selective cytotoxins against PANC-1 tumor cells
2017 · Nicholas Lorig-Roach, Frances Hamkins-Indik, et al. · Tetrahedron · 12
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity
2025 · Andrew T. Bockus, Siegfried S. F. Leung, et al. · Journal of Medicinal Chemistry · 9
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
2024 · Shilpa Singh, Catherine E. Gleason, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers
2026 · Justin A. Shapiro, Nathan J. Dupper, et al. · Journal of Medicinal Chemistry · 2
PDF
EP.03F.03 Orally Bioavailable Cyclin A/B Rxl Macrocycle has Antitumor Effect in SCLC & NSCLC Cell Line Derived (CDX) & Patient Derived Xenograft (PDX) Models
2024 · B. Levin, L.-F. Liu, et al. · Journal of Thoracic Oncology · 1
PDF
515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
2024 · M. Evangelista, E.W. Wang, et al. · European Journal of Cancer · 1
Abstract 5379: Macrocycles inhibiting RxL-mediated binding of substrates to Cyclin A are synthetic lethal in Rb mutated small cell lung carcinoma (SCLC)
2022 · Pablo D. Garcia, Catherine E. Gleason, et al. · Cancer Research · 1
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity
2025 · Shilpa Singh, Catherine E. Gleason, et al. · Journal of Thoracic Oncology
Abstract LB296: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/Chk1 DNA repair pathway
2025 · Catherine E. Gleason, Ranya Odeh, et al. · Cancer Research
Abstract 1560: Orally bioavailable macrocycles that target cyclins A and B RxL motifs cause tumor regression in xenograft models and in vitro show activity across multiple cancer types
2023 · Catherine E. Gleason, Pablo D. Garcia, et al. · Cancer Research
Works count: 11
Citation count: 50
H-index: 3
I10-index: 2
Year
Topic
Type